Provided are a STING mutant protein, a nucleic acid encoding the protein, a vector, a composition or vaccine comprising the protein or nucleic acid or vector, and a use of the protein in stimulating an immune response or treating cancer.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 15/70 - Vectors or expression systems specially adapted for E. coli
C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
The present application provides lipid nanoparticles comprising an ionizable lipid, a phospholipid, a structural lipid, and a PEG lipid. The lipid nanoparticles of the present application enable encapsulation and delivery of a therapeutic/prophylactic agent, safely deliver the therapeutic/prophylactic agent to a targeted position, and enable high expression, thereby exerting the effect of the therapeutic/prophylactic agent.
The present application disclosed a compound of formula (I) and a salt and a stereoisomer thereof, wherein each variable is as defined in the specification. The present application also disclosed a nanoparticle composition comprising the compound or a salt or a stereoisomer thereof, and the use of the nanoparticle composition for delivering active agents.
C07D 317/12 - Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
The invention provides a HPV mRNA lipid nanoparticle vaccine, comprising an open reading frame encoding a fusion protein of E2, E6 and E7 antigens of a high-risk HPV antigen. The invention also provides a method for treating and preventing HPV infection related diseases such as cervical cancer, cervical precancerous lesions, high-grade intraepithelial lesions of the cervix, high-grade squamous intraepithelial lesions (HSIL) or cervical intraepithelial neoplasia (CIN).
The present application discloses a compound having a structural formula as shown in formula (I), and a pharmaceutically acceptable salt or stereoisomer thereof. The present application further discloses a nanoparticle composition containing the compound or the pharmaceutically acceptable salt or stereoisomer thereof. The nanoparticles of the present application can efficiently deliver drugs and vaccines into cells, thereby achieving the treatment or prevention effects of drugs and vaccines.
C07C 229/12 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
Disclosed in the present application are a compound having a structural formula as shown in formula (I), and a pharmaceutically acceptable salt thereof or a stereoisomer thereof. Further disclosed in the present application is a nanoparticle composition containing the compound or the pharmaceutically acceptable salt thereof or the stereoisomer thereof. The nanoparticle of the present application can efficiently deliver a drug and a vaccine into a cell, thereby exerting the therapeutic or prophylactic purpose of the drug and the vaccine.
C07C 229/16 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
7.
POLYNUCLEOTIDE MOLECULES USED FOR THE PREVENTION OR TREATMENT OF HPV INFECTION RELATED DISEASES
The present application relates to a polynucleotide molecule that can be used for preventing or treatment HPV infection-related diseases, and a pharmaceutical product, a pharmaceutical composition, or an mRNA vaccine comprising said polynucleotide.
Disclosed in the present application are a compound having a structural formula as represented by formula (I), and a salt and an isomer thereof. Further disclosed in the present application is a nanoparticle composition containing the compound, or the salt thereof or the isomer thereof. The nanoparticle of the present application can efficiently deliver a drug or a vaccine into cells to exert the therapeutic or preventive purpose of the drug or the vaccine.
An engineered DNA molecule capable of being replicated in a cell, comprising a poly (A) tail coding sequence that makes the engineered DNA molecule more conservative when replicated in cells, particularly in prokaryotic cells, while adjusting the expression level of RNA in eukaryotic cells. Also provided are an RNA comprising the poly (A) tail and a use thereof.
Provided is an isolated mRNA molecule, which contains a nucleotide sequence encoding a chimeric immunogenic polypeptide, wherein the chimeric immunogenic polypeptide contains an immunogenic fragment of hemagglutinin (HA) of influenza A H5N1, an immunogenic fragment of hemagglutinin (HA) of influenza A H1N1, and an immunogenic fragment of hemagglutinin (HA) of influenza B Victoria, which are linked to each other. Further provided are a composition and vaccine containing the mRNA, a fusion protein encoded thereby, and a method using same for inducing an immune response to influenza virus in a subject.
A polynucleotide molecule for preventing or treating HPV infection-related diseases, and an mRNA vaccine, pharmaceutical composition or pharmaceutical product containing the polynucleotide.
C12N 15/37 - Papovaviridae, e.g. papillomaviruses, polyomavirus, SV40
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
The present application discloses a compound having a structural formula as shown in formula (I), and a salt and isomer thereof. The present application also discloses a nanoparticle composition comprising the compound or the salt or isomer thereof. The nanoparticle of the present application can efficiently deliver an active ingredient into a cell to achieve the purpose of treatment or prevention.
C07C 229/12 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
Provided is a method for preparing a circular RNA, which method comprises inserting purification tags, such as poly(A) tags or functional variants thereof into two terminal arms of a linear RNA precursor, and separating the circular RNA, which is obtained by means of the cyclization reaction of the linear RNA precursor, from other byproducts of the cyclization reaction as impurities using an affinity chromatographic medium capable of simultaneously binding to the tags. Further provided are a linear RNA precursor with a purification tag inserted in a specific region and an encoding DNA thereof. The insertion of the purification tag in the specific region does not affect the yield of linear RNA precursors produced by means of the in-vitro transcription (IVT) of the encoding DNA.
An engineered RNA molecule, a DNA molecule encoding same and the use thereof. The engineered RNA molecule comprises a poly-A tail sequence containing an MRNA binding site. The poly-A tail can be used to achieve accurate expression of the target gene in organs, tissues and/or cells.
The present disclosure relates to an ionizable lipid compound of formula (I), lipid nanoparticles comprising same, and preparation methods therefor and the use thereof, wherein variables are as defined in the specification.
C07C 229/26 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
C07C 229/22 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
C07C 229/36 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
C07D 233/64 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
The present application relates to a polynucleotide molecule that can be used for preventing or treatment HPV infection-related diseases, and a pharmaceutical product, a pharmaceutical composition, or an mRNA vaccine comprising said polynucleotide.
An engineered DNA molecule capable of being replicated in a cell, comprising a poly(A) tail coding sequence that makes the engineered DNA molecule more conservative when replicated in cells, particularly in prokaryotic cells, while adjusting the expression level of RNA in eukaryotic cells. Also provided are an RNA comprising the poly(A) tail and a use thereof.
A lipid compound as represented by the following formula (I) and a pharmaceutically acceptable salt or a stereoisomer thereof, and a nanoparticle composition thereof. Other substituents are as defined in the description. The nanoparticle composition can efficiently deliver drugs into cells to achieve the therapeutic or preventive purpose of the drugs.
The present application relates to a polynucleotide molecule that can be used for preventing or treating HPV infection-related diseases, and a pharmaceutical product, a pharmaceutical composition, or an mRNA vaccine comprising said polynucleotide.
The present application discloses compounds of formula (I) and salts and stereoisomers thereof, wherein the variables are as defined in the description. Further disclosed in the present application are nanoparticle compositions comprising the compounds, salts thereof, or stereoisomers thereof, and a use of the nanoparticle compositions for delivering an active agent.
C07D 319/06 - 1,3-DioxanesHydrogenated 1,3-dioxanes not condensed with other rings
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
21.
Long chain alkyl esteramine lipid compound, preparation method therefor and application thereof in nucleic acid delivery
The present invention relates to a long chain alkyl esteramine lipid compound as shown in Formula I, preparation method therefor as well as use thereof in nucleic acid delivery, the long chain alkyl esteramine lipid compound provided by the present invention has an excellent encapsulation rate and delivery effect as a lipid molecule in delivering disease treatment or preventive agents, showing lower toxicity and certain tissue distribution characteristics, and providing a basis of more selections for delivering disease therapeutic or prophylactic agents.
C07C 229/16 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
22.
LONG-CHAIN ALKYL ESTER AMINE LIPID COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN NUCLEIC ACID DELIVERY
Provided are a long-chain alkyl ester amine lipid compound represented by formula I, a preparation method therefor, and a use thereof in nucleic acid delivery. The long-chain alkyl ester amine lipid compound, as a lipid molecule, has excellent encapsulation efficiency and delivery effect in the delivery of disease treatment or a prophylactic agent, and also exhibits low toxicity and certain tissue distribution characteristics, providing more selective bases for the delivery of disease treatment or a prophylactic agent.
C07C 229/16 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
C07C 227/08 - Formation of amino groups in compounds containing carboxyl groups by addition or substitution reactions, without increasing the number of carbon atoms in the carbon skeleton of the acid by reaction of ammonia or amines with acids containing functional groups
C07C 227/18 - Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
C07C 229/12 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
The present disclosure relates to an mRNA vaccine based on a novel coronavirus, in particular to a mRNA vaccine for preventing or treating coronavirus infection, a synthesis method for the mRNA vaccine, and an RNA composition. In particular, the present disclosure relates to an mRNA vaccine for preventing coronavirus infection by inducing an effective coronavirus antigen-specific immune response. The present disclosure further describes a method for preparing the vaccine and immunological evaluation of the vaccine.
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
patents
